Q-omics provides the consensus-scored KIAA0319 profile across patient tissues and cancer cell-line models. KIAA0319 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KIAA0319 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, KIAA0319 RNA expression shows 18,716 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where KIAA0319 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA0319 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA0319 survival associations across molecular data types. KIAA0319 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA0319 RNA expression–survival associations across cancer types. High KIAA0319 expression shows unfavorable associations in UVM, LUAD, KIRP and LIHC, but favorable associations in OV and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KIAA0319 RNA expression.
This table summarizes KIAA0319 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KIAA0319. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA0319 shows lower tumor expression in KICH and higher tumor expression in KIRC, KIRP, HNSC, BRCA and THCA. The KIRC box plot shows higher KIAA0319 RNA expression in tumor versus normal tissue (log2 FC = +0.922, t-test p < 0.001).
This table shows molecular features associated with KIAA0319 in patient tissues and cancer cell lines. In patient samples, KIAA0319 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA0319 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
